Background--Major randomized trials assessing non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation generally excluded patients with hemoglobin <10 g/dL. This study evaluated the safety and effectiveness of NOACs in patients with atrial fibrillation and anemia.
unpredictably to anticoagulant therapy; thus, thromboembolic and bleeding-risk prediction scores may not be reliable. 10. Non-vitamin K antagonist oral anticoagulants (NOACs) are now widely used as alternatives to warfarin for preventing stroke in AF because NOACs are as effective as but safer than warfarin. [11] [12] [13] [14] The working dosage of NOACs is generally easier to ascertain because there is less variation among individuals and the drugs have a faster action onset and offset and exhibit fewer drug-food and drug-drug interactions than warfarin does. 15 However, most major randomized controlled trials of
NOACs have excluded patients with hemoglobin <10 g/ dL. 11, 13, 14, 16 In addition, there is no specific recommendation for anticoagulant therapy in anemic patients with AF and hemoglobin <10 g/dL in current guidelines. [17] [18] [19] Hence, the aim of the present study was to compare the safety and effectiveness of NOAC and warfarin when prescribed for stroke prevention in patients with AF and hemoglobin <10 g/dL.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
In this retrospective cohort study, patient data were collected from the Chang Gung Research Database, a deidentified database derived from the electronic medical records of the Chang Gung Memorial Hospital system in Taiwan. The Chang Gung Memorial Hospital is currently the largest Taiwanese medical care system, comprising 4 tertiary-care medical centers and 3 major teaching hospitals. This medical care system, with >10 000 beds and >280 000 inpatients per year, provides %10% of all medical service used by the Taiwanese people annually. [20] [21] [22] The hospital identification number of each patient was encrypted and deidentified to protect individuals' privacy. The diagnoses and laboratory data could be linked and continuously monitored using consistent data encryption. The institutional review board of Chang Gung Memorial Hospital approved the study protocol (approval serial No. 21080666B0).
The institutional review board waived the need for informed consents from the patients and prentices/guardians because the database used in this study consists of unidentifiable, secondary data released to the public for research.
Study Cohort
This study was conducted on the basis of electronic medical records in the Chang Gung Memorial Hospital system in Taiwan 2, or I48.91) and had had at least 1 prescription filled for oral anticoagulant therapy after diagnosis were included. We enrolled patients with AF, aged ≥65 years, because the Taiwan National Health Insurance only reimburses for NOAC prescriptions for these patients. The oral anticoagulant therapy consisted of warfarin or an NOAC (apixaban, dabigatran, edoxaban, or rivaroxaban). Patients were excluded if they had the following: (1) had deep vein thrombosis or pulmonary embolism up to 6 months before the index day (n=1040), (2) had received joint surgery (n=254) or a heart-valve replacement (n=653) up to 6 months before the index date, (3) had endstage renal disease before the index date (n=2331), (4) had IS or SE or died up to 7 days after the index date (n=3799), or (5) had not had data on hemoglobin levels for the 2 years before the index date (n=3199). After the exclusion, 8356 patients remained eligible for the study, and these patients were divided into 2 subgroups: patients with hemoglobin ≥10 g/dL (n=7687, 92.0%) and those with hemoglobin <10 g/dL (n=669, 8.0%). [9] [10] [11] 14 The Figure is the flowchart of the enrollment process and the subdivision of the eligible study cohort into the 2 subgroups. The index date was defined as the first date on which warfarin or NOAC therapy was initiated. The risks of IS/SE, bleeding, and death were compared between NOAC and warfarin therapies in these 2 subgroups of anticoagulated patients with AF. The
Clinical Perspective
What Is New?
• Non-vitamin K antagonist oral anticoagulants, compared with warfarin, were associated with a significantly lower risk of major bleeding or gastrointestinal tract bleeding, but there was no difference in ischemic stroke, systemic embolism, or death in anemic patients with atrial fibrillation patients and hemoglobin <10 g/dL.
What Are the Clinical Implications?
• Non-vitamin K antagonist oral anticoagulant is a favorable alternative to warfarin in patients with atrial fibrillation and anemia, ≥65 years.
identified patients were followed up until the outcome event or the end of 2017, whichever occurred first.
Assessment of Other Covariates
Baseline comorbidities of the study cohort included diabetes mellitus, hypertension, chronic kidney disease, chronic liver disease, and histories of heart failure, myocardial infarction, transient ischemic attack, IS, SE, bleeding, peptic ulcer disease, and cancer. Laboratory data included serum hemoglobin, platelet counts, estimated glomerular filtration rate, liver function tests, and lipid profiles. Baseline medications were identified from medical records for the 180-day period before the index date, including antiplatelets, nonsteroidal anti-inflammatory drugs, statins, amiodarone, digoxin, and proton pump inhibitors. 
Outcome Measures
The efficacy end point was the occurrence of IS/SE or death. The safety end point was the occurrence of major bleeding or gastrointestinal tract bleeding. Major bleeding was defined as clinically overt bleeding associated with at least a 2-g/dL decrease in hemoglobin or requiring a transfusion of at least 2 units of packed red blood cells or whole blood, fatal bleeding, or intracranial hemorrhage during the period of drug use or within the 14-day period after the last day of drug use.
Gastrointestinal tract bleeding was defined as hospitalization with a primary diagnosis of bleeding in any segment of the gastrointestinal tract, from the esophagus to the rectum, during the drug-use period or within the 14-day period after the last day of drug use. The follow-up period was defined as the time from the index date to the first occurrence of any study outcome or the end date of the study period (December 31, 2017), whichever came first. The anticoagulant type was treated as a time-dependent exposure. A 14-day period was the censoring window for drug switches. If an event occurred during the initial therapy period or within the 14-day period after the switch, the event and time were ascribed to the initial therapy. If an event occurred ≥15 days after the switch, the event and time were ascribed to the switch therapy. The diagnostic codes used to identify the study outcomes and the baseline covariates are summarized in Table S1 .
Statistical Analysis
Data were presented as the meanAESD or median (interquartile range) for continuous variables and as proportions for categorical variables. Differences between continuous values were assessed using Wilcoxon's rank-sum test. Differences between nominal variables were compared with a v 2 test. We calculated event rates as the number of events divided by 100 person-years. The Cox proportional hazard regression with time-dependent exposure (anticoagulant type) was used to compare event rates between NOAC and warfarin therapies in the 2 groups of patients. When comparing the risk of IS/SE, major bleeding, gastrointestinal tract bleeding, or death between NOAC and warfarin therapies, the analyses were adjusted for covariates, including patient characteristics, baseline comorbidities, laboratory information, and baseline medications. Statistical significance was based on the level of a=0.05. All analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC).
Sensitivity and Subgroup Analyses
We performed 3 sensitivity analyses to validate our findings and check for potential selection biases. First, given the high mortality risk in patients with AF and anemia, we reanalyzed the data accounting for competing risks of death. Second, we reanalyzed the data by using 7 days as a censoring window for drug switches to assess whether the primary findings would have been changed if differential censoring windows between drug switches had been used. Third, we reanalyzed the data after excluding patients with missing values of covariates in the models to determine if missing data would change the results. Subgroup analyses were performed to explore the effects of anticoagulant types in patient subgroups with and without a history of peptic ulcer disease or cancer.
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Results Baseline Characteristics Of the 669 patients with hemoglobin <10 g/dL, 446 (66.7%), 184 (27.5%), 25 (3.7%), and 14 (2.1%) had hemoglobin levels of 9 to 9.9, 8 to 8.9, 7 to 7.9, and <7 g/dL, respectively. Both CHA 2 DS 2 -VASc and HAS-BLED scores were significantly higher in the patient subgroup with hemoglobin <10 g/dL.
Patients with hemoglobin <10 g/dL tended to be older, to be women, and to have more comorbidities and a history of heart failure or stroke. In summary, patients with hemoglobin <10 g/dL were older and weaker than those with hemoglobin ≥10 g/dL. A separate comparison between NOAC and warfarin users in the patient subgroup with hemoglobin <10 g/dL is given in Table 2 . Within the group, patients using NOAC or warfarin had similar demographic characteristics and comorbidities, except for older age in NOAC users. 
Patients With Hemoglobin ≥10 g/dL

Sensitivity and Subgroup Analyses
The results were similar for IS/SE and bleeding when death was treated as a competing risk factor in the Cox model (Table 3) . We reanalyzed the data by using 7 days as a censoring window for drug switches and found similar results to those obtained with a 14-day censoring window (Table S2) . Table S3 shows the analysis results after excluding patients with missing values of covariates; the results were similar to the main results. For the subgroup analysis of patients with and without a history of cancer (Table 4) or peptic ulcer disease (Table 5) , the results were generally consistent with the main results. The lower risks of major bleeding and gastrointestinal tract bleeding associated with NOAC therapy were similar in patients with and without a history of cancer or peptic ulcer disease. However, extreme caution needs to be taken when interpreting the subgroup analyses because of the limited sample size and number of events. The number of events is way below the general rule of thumb.
Discussion
The main findings of the present study are as follows: (1) Approximately 8% of patients with AF had a hemoglobin <10 g/dL when they were anticoagulated. (2) In patients with AF and hemoglobin <10 g/dL, NOAC therapy was associated with a significantly lower risk of major bleeding or gastrointestinal tract bleeding when compared with warfarin therapy, and there was no statistical difference between the 2 therapies in terms of their risk of IS/SE or death. This better [3] [4] [5] 17 Anemic patients with AF requiring anticoagulation were less likely to receive warfarin therapy because of bleeding concerns, and they more often discontinued warfarin therapy than nonanemic patients with AF. 26 In a subgroup analysis of the J-ROCKET AF (Japanese-ROCKET AF) trial, baseline anemia with warfarin therapy was one of the independent predictors of bleeding events. 6 In addition, patients with AF and anemia were also associated with a higher prevalence of stroke, a higher CHA 2 DS 2 -VASc score, and a greater risk of IS/SE. 1 Similar to the study of patients with mild anemia in the ARISTOTLE trial, 1 the present study found that patients with hemoglobin <10 g/dL were older, more likely to be women, and more likely to have experienced prior heart failure and stroke than patients with hemoglobin ≥10 g/dL. Both CHA 2 DS 2 -VASc and HAS-BLED scores were significantly higher in the anemic group. In these patients, NOAC therapy resulted in a similar reduction in the event rates of IS/SE and death and a significantly lower risk of major bleeding or gastrointestinal tract bleeding than warfarin. Anemic patients with AF receiving anticoagulant therapy require more extensive follow-up because of their increased risks of bleeding and the high probability of anticoagulant interruptions. In the present cohort, 8% of the patients initiating oral anticoagulant therapy had a baseline hemoglobin level <10 g/dL. Before NOAC therapy can be initiated in such patients, their history of bleeding and clinical conditions that are likely to result in bleeding (ie, peptic ulcer disease, impaired renal or liver function, anemia, and thrombocytopenia) should be investigated, and corrected, if reversible. 17, 18 Medications that could increase the risk of major bleeding, such as nonsteroidal anti-inflammatory drugs or antiplatelets, should be avoided or balanced with the risk and benefit of anticoagulant therapy. For patients receiving an NOAC therapy, it may be recommended to follow up the hemogram 1 month after anticoagulant initiation and then every 6 to 
Study Strengths
The strengths of our study include using a large, well-defined population sample; available baseline hemoglobin, platelet count, renal function, and liver function data before the initiation of oral anticoagulant therapy; and a direct comparison of NOAC and warfarin therapies in patients with hemoglobin levels <10 g/dL and ≥10 g/dL. To our knowledge, this is 1 of the only 2 studies that have compared NOAC therapy and warfarin therapy in patients with AF and hemoglobin <10 g/dL.
1
Study Limitations
This study has several limitations. First, miscoding and misclassification are potential sources of biases in a database that relies on physician-reported diagnoses. However, such miscoding and misclassification are unlikely to have differed systematically between the 2 subgroups of patients, and our findings that NOAC was safer than warfarin and equally effective in patients with hemoglobin ≥10 g/dL agreed with metaanalysis and real-world data. 27, 28 Second, because this study was a retrospective data analysis rather than a randomized controlled trial, both selection bias and unmeasured confounders were evident, despite statistical adjustments. Third, we did not assess the quality of warfarin control by calculating the time in therapeutic range because there were many missing values for prothrombin time from the follow-up period. In Taiwan, the measured time in the therapeutic range measured in one study is 56.6%, 29 which is lower than for the white or Japanese populations. The observed benefit of lower bleeding risks in NOACs might disappear when they were compared with well-managed warfarin. 30 Further studies to generalize and apply the findings of this study to other populations are, thus, warranted. Fourth, the sample size for patients with hemoglobin <10 g/dL was only 669. The small sample may not be sufficient to establish the efficacy and safety of NOACs and limit the generalization of the results. Similarly, given the limited patient number and event number in each subgroup, extreme caution is needed in the interpretation of subanalysis results.
Conclusions
In patients with AF and hemoglobin <10 g/dL, NOAC therapy was associated with lower risks of major bleeding or gastrointestinal tract bleeding than warfarin therapy, and the 2 therapies showed no significant difference in the risk of IS/SE or death. 
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